Navigation Links
Tecfidera's Patient Share at Three Months Postlaunch Surpasses That for Aubagio and Gilenya At the Same Stage of Their Launches
Date:8/28/2013

EXTON, Pa., Aug. 28, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that patient share for Biogen Idec's Tecfidera among relapsing-remitting multiple sclerosis (RR-MS) patients treated with disease modifying therapy (DMT) has doubled from two percent at one month postlaunch to four percent at three months postlaunch. In fact, despite being the third oral DMT to reach the MS market, patient share for Tecfidera exceeds that for the first two oral DMTs for MS—Sanofi/Genzyme's Aubagio (1 percent) and Novartis's Gilenya (1 percent)—at the same stage of their respective launches. Current physician trial rate for Tecfidera (65 percent) beats that for Aubagio (33 percent) and Gilenya (53 percent).

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36805LOGO )

The recently published LaunchTrends: Tecfidera Wave 2 report finds that, although neurologists continue to identify Tecfidera's oral formulation as the product's biggest advantage, their positive perceptions related to Tecfidera's efficacy and safety profile likely drives initial uptake and continued use among prescribers, underscoring the importance neurologists assign to a drug's risk/benefit profile rather than its mode of administration.

Representing a shift from two months ago, Tecfidera is now the DMT least associated with managed care coverage. Feedback from qualitative interviews suggests that some Tecfidera prescribers have experienced difficulties with managed care approval of Tecfidera, especially among treatment-naive patients, with prescribers reporting that insurance companies often require patients to have failed one of the platform injectable DMTs prior to Tecfidera use. Consequently, Tecfidera prescribers report that the majority of Tecfidera prescriptions need some requirement for managed care approval, most often prior authorization but also step therapy. However, the majority of Tecfidera prescribers continue to rate Tecfidera's managed care approval process as being either moderately difficult or easy.   

Over the next six months, Tecfidera's patient share among DMT-treated RR-MS patients is anticipated to increase significantly to 16 percent, being driven by continued use among current prescribers and initial uptake among current nonprescribers.

"This finding suggests that, even at this early stage of market entry, Tecfidera is becoming the oral DMT of choice for neurologists, while patient shares for Aubagio and Gilenya are expected to grow much more modestly over the same time period," said BioTrends Research Group Senior Business Insights Analyst Emma Williams, Ph.D. "However, despite this enthusiasm for Tecfidera, a stable patient population and managed care issues will likely curb Tecfidera's use to some extent."

About BioTrends Research Group
BioTrends Research Group provides syndicated and custom primary market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please visit www.bio-trends.com. BioTrends is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.

For more information, contact:

Decision Resources Group
Christopher Comfort
781-993-2597
ccomfort@dresources.com


'/>"/>
SOURCE BioTrends Research Group
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Study Showed Patients Treated With The miraDry© System Experienced 82 Percent Sweat Reduction On Average
2. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
3. Watching, Reading and Listening: A New Way to Interact with Patient Information
4. Phreesia identifies over 26% of patients who require additional autism evaluation
5. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
6. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
7. Onyx Pharmaceuticals Announces FDA Advisory Committee to Review Carfilzomib for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
8. New post-hoc analyses examined Neupro® effects on pain, depressed mood, apathy and fatigue in patients with Parkinsons disease
9. Patient Advocate Foundation Announces New Co-Pay Relief (CPR) Offerings for Patients Facing Health Issues Due to Electrolyte Imbalance
10. Quest Diagnostics Establishes Unique Healthcare Identifier to Improve Access to Vital Patient Health Information; 80 Million Patient IDs Created to Date
11. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , Feb. 8, 2016 ... the "Global Skin Protective Equipment Market 2016-2020" ... --> http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced the addition ... 2016-2020" report to their offering. ... ) has announced the addition of the ...
(Date:2/8/2016)... 2016   Intarcia Therapeutics, Inc. today announced ... into the newly created role of Vice President, Head ... has two decades of leadership experience at leading pharmaceutical, ... academic medical center. Most recently Dr. Yee served as ... US Head Medical Officer at AstraZeneca, where he led ...
(Date:2/8/2016)... 8, 2016  The University of Michigan Health System ... that, as part of the development of four new ... hospitals in the U.S. to start using new top-of-the-line ... U-M,s chair of neurosurgery. --> Karin ... --> The BrightMatter technology from Synaptive Medical – ...
Breaking Medicine Technology:
(Date:2/8/2016)... ... February 08, 2016 , ... The Federal ... federallabs.org . The site houses a wealth of federal resources that businesses ... the process called technology transfer (T2). As a network of over 300 federal ...
(Date:2/8/2016)... Houma, LA (PRWEB) , ... February 08, 2016 ... ... Louisiana from offices in Houma, LA, celebrates the beginning of a new charity ... raised to assist Court Appointed Special Advocates (CASA). In the belief that children ...
(Date:2/8/2016)... Minn. (PRWEB) , ... February 08, 2016 , ... ... the BantamPro L top-load case packer for pouches, bags, and flow wrapped products ... to help co-packers and specialty product manufacturers step up to semi-automatic or fully-automatic ...
(Date:2/8/2016)... ... , ... Steve Helwig & Associates Insurance & Financial, serving the families of ... up with Citizens Opposed to Domestic Abuse in support of its efforts to provide ... victimized by the fear of violence in their own homes, donations may now be ...
(Date:2/8/2016)... (PRWEB) , ... February 08, 2016 , ... Delta Dental ... to help combat pancreatic cancer. , Gary D. Radine, who recently retired as president ... the American Cancer Society’s 2015 CEO of the Year , helped lead the ...
Breaking Medicine News(10 mins):